Overview

Combination Gel and Vascular ND in Mild to Moderate Rosacea

Status:
Completed
Trial end date:
2011-02-01
Target enrollment:
Participant gender:
Summary
This is a single center, open-label, split-face, prospective study of ten to fifteen subjects seeking vascular laser therapy for the treatment of mild to moderate rosacea. Subjects will be screened for eligibility for vascular laser therapy outside of the confines of this protocol. Once approved for laser, subjects will be screened for study enrollment and topical treatment of their rosacea at the Screening/Baseline visit. All subjects will receive Finacea 15% gel and will be instructed to apply the study drug to one half of the face, twice daily. Drug application will be modified just prior to and after the subjects' laser treatment to reduce irritation. Subjects will undergo Vascular Nd:Yag laser therapy to involved areas over the whole face two weeks after initiating Finacea treatment. Subjects will continue to use Finacea gel to one half of the face for the duration of the study.
Phase:
N/A
Details
Lead Sponsor:
Wake Forest University Health Sciences
Collaborator:
Bayer
Treatments:
Azelaic acid